The aim of this work was to determine the effect of various concentrations of gemcitabine on the vascular endothelium in the rat. A total of 62 animals were used in the experiment. Gemcitabine was administered in the recommended dose (20 mg) or in the double (40 mg) or triple recommended dose (60 mg) into the abdominal aorta, splenic artery, common iliac artery, portal vein, or the jugular vein. After various intervals of survival, specimens of the vascular wall were collected for histological examination. Saline solution was administered into the vessels of the control-group of animals. The work has shown that gemcitabine at the standard, double or triple dose does not cause any serious changes to the vascular endothelium.
Healthy rats were randomly assigned to the treatment and control groups. A pilot study was first performed in order to establish the variance of results. Statistical analysis of variance was used in the evaluation of the results.
The rats were operated on an experimental surgical table, fixed on a pad, lying on their backs with upper and lower extremities stretched out. The surgery was performed under general anaesthesia (xylazine with ketamine hydrochloride) and aseptic conditions.
The body surface of the experimental animals was assumed to amount to 200 cm -2 . A dose of 20 mg of gemcitabine corresponds to this body surface. The animals were assigned to five groups: the animals were given 20 mg of gemcitabine in the first treatment group, the double of this dose (40 mg) in the second group, the triple dose (60 mg) in third group, and the nine-fold quantity (180 mg) in the fourth group. In the fifth (control) group, saline was administered into the blood vessels of the rats instead of gemcitabine.
Gemcitabine was administered by slow infusion with an especially finished needle of the smallest diameter (0.33 × 12 mm) so that the traumatism to the vascular wall be minimised. After opening the abdominal cavity by median laparotomy, the drug was administered into either the abdominal aorta or the splenic artery or the common iliac artery or the portal vein. The site of the drug administration was then followed up for possible bleeding and it was marked with a clip. Then the abdominal cavity was carefully stitched up and the animal was wakened. Most often, gemcitabine was administered into the jugular vein (i.e. without laparotomy). At pre-set time intervals, the experimental animals were euthanised with a Thiopental injection into the thoracic cavity. Specimens of the relevant marked vessel were taken starting at the site of injection and further in the blood flow direction for the histological examination of the possible damage to the vascular wall.
The results were analysed statistically with Fisher's exact test, using the software CSS: STATISTICA, version 3.1 company manual of StatSoft Tulsa, OK 74104, USA.
The histologically established damage to the vascular wall was categorized into four degrees: Degree 0 represented vessels without demonstrable signs of damage. Degree 1 included cases with stagnating erythrocytes or mildly changed properties of the endothelium. Animals with mild swelling of the endothelium represented the degree 2. Degree 3 included cases of possibly serious damage to the vascular endothelium.
The experimental work was approved by the Ethics Committee of the St. Anna Teaching Hospital, and also by the Expert Committee for the Work with Experimental Animals of the Masaryk University Medical Faculty in Brno (No 26/97).
Results and Discussion
The degree of vascular wall damage in dependence on the administered dose of gemcitabine and the days elapsed from the drug administration to the collection of histological specimens is shown in Table 1 .
When a dose of gemcitabine exceeding the triple of the recommended dose was used in the pilot experiment, the experimental animals died due to toxicity of the drug. In all such cases necrosis of the liver and spleen was found in the histological examination. Therefore we only used the 60 mg dose of gemcitabine as the maximum dose in the main experiments (i.e. the triple of the standard dose).
In no case the degree 3 damage to the vascular endothelium was found. The 0 dose of gemcitabine means that 1 ml of saline was injected into the vessel instead of gemcitabine.
In the first evaluation of the effect of gemcitabine, the number of control animals with and without endothelium damage was compared with the total number of treated animals again with and without damaged vascular endothelium. Fisher's exact test was used for the evaluation of the inter-group differences with the resulting values of p = 0.037. Because this result was unexpected (the control group showed greater damage than the treatment group), the two-sided variant of the test was used, which yielded the value of p > 0.05. Thus the effect of gemcitabine on the vascular wall cannot be considered significant.
Using a similar technique, the numbers of animals with and without vascular wall damage were compared with respect to the dose of gemcitabine. Even here the results were not statistically significant.
There was no statistically significant difference due to the dose of gemcitabine applied into the blood vessel and the degree of the cell wall damage (Table 2) .
Undoubtedly the changed haemodynamics caused by the administration of the drug can cause changes to the vascular endothelium. In spite of this, in most cases the vascular endothelium being examined showed no signs of "breaking" and the changes observed rather corresponded to normal variants. No signs giving evidence for the necrosis or destruction of the vascular endothelium or for its separation were observed. In no case serious changes to the cell wall were observed (degree 3 damage) after the administration of gemcitabine into the vascular lumina.
Our work has demonstrated that even the double or triple standard dose of gemcitabine administered into the blood vessel with the purpose of potential chemotherapy resulted in no serious changes to the vascular endothelium and the cell wall.
Vliv gemcitabinu na cévní endotel u potkana
Cílem práce bylo ovûfiit úãinek rÛzn˘ch koncentrací gemcitabinu na cévní endotel u potkana.V experimentu bylo pouÏito celkem 62 zvífiat. Do abdominální aorty, a. lienalis, a. iliaca communis, v. portae, nebo v. jugularis byl aplikován gemcitabine v doporuãené dávce, nebo dvojnásobku doporuãené dávky, nebo trojnásobku doporuãené dávky. Po rÛznû dlouh˘ch intervalech pfieÏívání byly provedeny odbûry cévní stûny k histologickému vy‰etfiení. Kontrolní skupinû zvífiat byl aplikován do cév fyziologickȓ oztok. V práci bylo prokázáno, Ïe gemcitabin v dvojnásobné, ani trojnásobné dávce nezpÛsobil Ïádné závaÏné zmûny na cévním endotelu. 
